Home » Newsletters » BioWorld Science

BioWorld Science

July 30, 2004

View Archived Issues

Inhibition of beta-amyloid plaque formation by Cu/Zn chelating agent

Launch of Axid oral solution

New factor VIIa/TF inhibitors under study at Schering AG

Chinese researchers identify novel agents for renal disorders

Novel antitumor and antifungal compounds developed at Gemin X

New orexin-2 antagonists and their use in obesity and sleep disorders

New PTP-1B inhibitors described by Wyeth researchers

GSK researchers design novel thrombin/factor Xa inhibitors

Novel VEGFR inhibitors prepared and tested by ImClone researchers

Phase I results of spi-VEC vaccine for hepatitis B

Endovasc updates pipeline progress

FDA approval for Metvix

Maribavir enters phase II program in bone marrow transplant patients

Lexicon Genetics and Takeda team up on hypertension

Alimta receives positive endorsement from Advisory Committee for NSCLC

Approvable letter for Ionsys

Enanta and Shionogi enter agreement for EP-013420 in Japan and East Asia

Sunesis and Merck & Co. collaborate on discovery of novel antiviral drugs

EstroGel becomes first available transdermal estrogen gel in U.S.

Potent antiinflammatory and analgesic agent identified and tested at Orchid

Plantacor licenses preclinical cancer therapeutics from M. D. Anderson

Restructuring and R&D refocusing at Inflazyme

Completion of clinical portion of EXCEEDS phase IIIb study of Xyrem

PediaMed and Allergan enter pediatrics copromotion agreement for Tazorac

Neurokinin 1 receptor antagonist effective against postoperative fibrous adhesions

ChiRhoClin launches human secretin

Assessment of Bcl -2 family members as targets for antisense therapy in melanoma

Immunostimulatory effects of loxoribine in monocyte-derived DCs

Photodynamic therapy with Metvix shows efficacy in actinic cheilitis

MRI improvements found with a single dose of natalizumab in relapsing MS patients

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 21, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 21, 2026.
Cell/gene therapy sector now sustainable; China competition mounting
BioWorld
There was an upbeat message for cell and gene therapy companies in the 2026 industry update presented as the J.P. Morgan Healthcare Conference opened on Monday,...
Abbvie snags PD-1/VEGF bispecific in potential $5B Remegen deal
BioWorld
With rumors regarding a couple of potential mega-mergers making the rounds, the week of the annual J.P. Morgan Healthcare Conference kicked off with the official...
Neurotrimin unveiled as marker in intellectual disability
BioWorld Science
Neurotrimin (NTM) is a member of the IgLON family, the disruption of which has been tied to emotional learning deficits and anxiety-like behavior in animal...